---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-036597"
form_type: "8-K"
ticker: "ESPR"
cik: "0001434868"
company_name: "Esperion Therapeutics, Inc."
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:00:07.158058+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Esperion Q2 revenue jumps 186% to $73.8M; monetizes European royalties for $304.7M

## Summary
- Total revenue $73.8M (+186% YoY); U.S. product revenue $28.3M (+39% YoY).
- Monetized European royalties to OMERS for $304.7M; used proceeds to pay off Oberland facility and remove liens.
- Net loss $61.9M ($0.33 loss per share) vs $49.9M loss in Q2 2023; cash $189.3M.
- Retail prescription equivalents increased 11% in final four weeks of Q2; >21,000 prescribers.
- Reiterated FY2024 operating expense guidance $225M-$245M; patent extension for bempedoic acid to Dec 2030.

## SEC filing metadata
- accession: 0001628280-24-036597
- form_type: 8-K
- ticker: ESPR
- cik: 0001434868
- company_name: Esperion Therapeutics, Inc.
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434868/000162828024036597/0001628280-24-036597-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434868/000162828024036597/espr-20240812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-036597
- JSON: https://secwatch.observer/filing/0001628280-24-036597.json
- Plain text: https://secwatch.observer/filing/0001628280-24-036597.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.